Search the Newsreel

Kaltura (Nasdaq: KLTR) buys PathFactory and posts $5.5M Q2 loss

Kaltura (Nasdaq: KLTR) reported Q2 2026 revenue of $46.9 million, an increase from $44.5 million in the prior year, primarily driven by subscription revenue. Despite narrowing its operating loss, the company posted a net loss of $5.5 million for the quarter. Kaltura also announced …

Kaltura Number of Employees 2026 | Employee Count & Headcount Data

Kaltura, Inc. (KLTR) had approximately 495 employees worldwide as of March 2026, marking a 22.1% decline from 635 employees in 2023. The company is actively hiring, with 34 job postings in 2026, though this is a 52.2% decrease from 2025. Kaltura's workforce is concentrated …

Kaltura Inc 2026: Revenue $46.89M, EPS ($0.04) — 10-Q Summary

Kaltura Inc (KLTR) reported its second-quarter 2026 results, showing a revenue increase to $46.89 million from $44.46 million year-over-year. The company significantly reduced its net loss to ($5.54 million) from ($7.75 million) in Q2 2025, with diluted loss per share narrowing to ($0.04) from …

Kaltura Q2 Earnings Call Highlights

Key Points Interested in Kaltura, Inc.? Here are five stocks we like better. Q2 results exceeded guidance: Revenue rose 5% year over year to $46.9 million, subscription revenue increased 8% to $45.6 million, and adjusted EBITDA jumped 44% to $5.9 million. Non-GAAP gross margin …

Kaltura Q2 2026 Earnings: Subscription Growth Expands Gross Margin

Kaltura reported Q2 2026 revenue of $46.9 million, a 5% increase year-over-year, with GAAP diluted loss per share improving to $0.04. Subscription growth and reduced cost of revenue led to a higher GAAP gross margin of 74%, despite operating cash flow turning negative and …

Kaltura (Nasdaq: KLTR) grows Q2 2026 revenue and boosts margins

Kaltura (Nasdaq: KLTR) reported strong second-quarter 2026 financial results, exceeding guidance with total revenue of $46.9 million and a non-GAAP net profit of $2.3 million. The company achieved a record non-GAAP gross margin of 75% and its highest second-quarter Adjusted EBITDA to date at …

Laba Kalbe Farma (KLBF) Turun Tipis di Semester I-2026, Cek Rekomendasi Sahamnya

Why Is Kalgoorlie Gold Mining (ASX:KAL) Pinjin Drilling Restart in Focus?

Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% - Here's What Happened

Kalaris Therapeutics (NASDAQ:KLRS) saw its shares jump 15.4% to $4.05 in midday trading, despite lower-than-average trading volume. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $18.75. Insider activity shows Director Srinivas Akkaraju recently purchased 244,300 shares, increasing his holdings …

Kaltura's AI avatars can now read your tone and change expressions

Kaltura (Nasdaq: KLTR) has introduced real-time emotional intelligence for its Agentic Avatars, allowing them to interpret user tone and conversational intent. These avatars can now respond with synchronized facial expressions and vocal nuance, making AI interactions more natural and engaging. This technology is designed …

Kalgoorlie Gold Mining (ASX: KAL) Share Price Drops Nearly 20% - Here’s Why

Kalpataru Projects hosts earnings call on Aug 11 for Q4FY26 results

Kalpataru concludes Q1 FY27 earnings call, audio recording now available

KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders

Abbott Cooper PLLC has initiated an investigation into Kalaris Therapeutics, Inc. (formerly AlloVir, Inc.) regarding potential breaches of fiduciary duties by its board of directors. The investigation focuses on stockholders who continuously held shares prior to November 7, 2024. The firm is offering legal …

Kalaris Therapeutics director Laurie Keating files initial beneficial ownership statement

Kalaris Therapeutics director Laurie Keating filed an initial Form 3 on August 3, 2026, disclosing her holdings as of August 1, 2026. This news brief was generated by Public Technologies (PUBT) using AI and is based on original content published by Kalaris Therapeutics Inc. …

Kalyani Investment Company Limited announces Annual dividend, payable on September 25, 2026

Kaltura Inc expected to post a loss of 1 cent a share - Earnings Preview

Kaltura Inc (KLTR) is anticipated to report an earnings loss of 1 cent per share. This information comes from a Refinitiv earnings preview. Full access to the Reuters article is available through a TradingView subscription.

Kalpataru narrows Q1 loss to ₹27 crore on higher revenue, collections

Kalyani Investment Company schedules AGM for Sep 17 via VC

Kalamazoo to Release Escrowed Shares Tied to Xanadu Gold Acquisition

Chemfab Alkalis net profit surges 124% in Q1FY27 on tax credit

Earnings Preview: Kaltura to Report Financial Results Pre-market on August 05

Kaltura (NASDAQ: KLTR) is expected to announce its financial results before market open on August 5th. Analysts predict an average EPS of -$0.09 and revenue of $42.52 million. Investors will be keen to see if the company can meet or exceed these estimates.

Kaltura Inc (KLTR) Institutional Confidence

Kaltura Inc (KLTR) has an institutional shareholding score of 3.00, placing it 283rd out of 486 companies in the Software & IT Services industry. The latest institutional shareholding proportion stands at 37.64%, which is a 19.12% decrease quarter-over-quarter. James Simons is identified as the …

Kalamazoo Resources Cash Position Falls as Exploration Spending Intensifies

Alkali Metals Ltd. Revenue Breakdown – NSE:ALKALI

KLRS|Kalaris Therapeutics Inc|Price:3.380|Chg%:+0.040

Kalaris Therapeutics Inc (KLRS) shows healthy fundamentals and significant growth potential, despite recent weak stock market performance. Its valuation is considered fair within the Biotechnology & Medical Research industry, and institutional ownership is very high. Analysts have rated it as a Buy with a …

Buy, Sell Or Hold: Waaree Energies, SBI Funds, Nestle, Motilal Oswal Financial Services, Thangamayil, Kalamandir — Ask Profit

Alkali Metals Standalone June 2026 Net Sales at Rs 17.57 crore, down 14.78% Y-o-Y

Hikal Q1 FY27 Earnings Call Scheduled for August 6 at 5 PM IST

Kalyani Steels Final Dividend Ex-Date Tomorrow for Rs 10 Per Share Payout; Stock Closes 1.71% Lower in...

Should You Buy Sai Silks (Kalamandir) Limited (NSE:KALAMANDIR) For Its Upcoming Dividend?

Chemfab Alkalis consolidated net profit rises 124.71% in the June 2026 quarter

Price to sales forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS

This article focuses on Kalaris Therapeutics, Inc. (NASDAQ: KLRS) and its "Price to sales forward" metric. It appears to be a financial data page from TradingView, offering an overview of the company's financials without providing detailed analysis in the content given. The page structure …

Kaltura CCO Natan Israeli sells $150 in KLTR stock

Kaltura's Chief Customer Officer, Natan Israeli, recently sold 100 shares of KLTR stock for $150. The sale was executed under a Rule 10b5-1 trading plan. This transaction comes as Kaltura's stock trades below the sale price and is considered overvalued by InvestingPro, with earnings …

Kaltura Positioned as a Leader in the 2026 IDC MarketScape for Worldwide Virtual Events Applications

Kaltura has been recognized as a Leader in the 2026 IDC MarketScape for Worldwide Virtual Events Applications, reflecting its strengths in driving engagement, interaction, and retention for virtual events. The company's platform incorporates agentic AI capabilities, including Agentic Avatars for personalized attendee experiences and …

Kalaris Therapeutics Inc (KLRS) Valuation: PE, PB & Fair Value Analysis

Kalaris Therapeutics Inc (KLRS) has a current valuation score of 6.34, ranking 325 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio is -4.24, which is significantly below its recent high and above its recent low. Key valuation metrics …